Evidence map›Paper›PMID 40917018›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Enzalutamide-Resistant STEAP4

Wenhao Wang, Jing Zhao, Tiewen Li, Guangjian Fan, Jianong Zhang, Chenghao Zheng, Zhiwen Xie, Yu Zhang, Chengling Feng, Tianyu Cao and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Enzalutamide-Resistant STEAP4Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Wenhao WangDepartment of Urology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China.
Jing ZhaoDepartment of Urology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China.
Tiewen LiDepartment of Urology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China.
Guangjian FanDepartment of Urology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China.
Jianong ZhangDepartment of Urology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China.
Chenghao ZhengDepartment of Urology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China.
Zhiwen XieDepartment of Urology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China.
Yu ZhangDepartment of Urology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China.
Chengling FengDepartment of Urology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China.
Tianyu CaoDepartment of Urology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China.
Jianyin LiDepartment of Urology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China.
Guomin JuDepartment of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Di CuiDepartment of Urology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China.
Shujie XiaDepartment of Urology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China.
Bangmin HanDepartment of Urology, School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, 200080, China.ORCID https://orcid.org/0000-0001-9101-8377

Funding

Beijing Life Oasis Public Service CenterNational Natural Science Foundation of China 82072849National Natural Science Foundation of China 82102857
6 · The paper itself

Abstract

Despite the expanding clinical application of second-generation anti-androgens like enzalutamide (ENZ) in hormone-sensitive prostate cancer (HSPC), therapeutic resistance culminating in castration-resistant prostate cancer (CRPC) persists as an unresolved clinical crisis. Through comprehensive single-cell transcriptomic profiling of ENZ-naïve and ENZ-treated tumors, an expansion of ENZ-resistant myofibroblastic cancer-associated fibroblast (designated STEAP4

Indexed as

Antineoplastic Agents, HormonalCancer-Associated FibroblastsDrug Resistance, NeoplasmPhosphatidylcholinesProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overAnimalsAutophagyBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBenzamidesCholine-Phosphate CytidylyltransferaseDisease ProgressionGene Expression Regulation, NeoplasticHSP90 Heat-Shock ProteinsHumansAntineoplastic Agents, HormonalBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBenzamidesCholine-Phosphate CytidylyltransferaseenzalutamideHIF1A protein, humanHSP90 Heat-Shock ProteinsHypoxia-Inducible Factor 1, alpha SubunitMembrane ProteinsNitrilesOxidoreductasesPCYT1A protein, humanPhenylthiohydantoinPhosphatidylcholinesSTEAP4 protein, humanTFE3 protein, humanautophagycancer‐associated fibroblastsenzalutamidephosphatidylcholineprostate cancerstemness

Identifiers

PMID40917018
PMCPMC12667479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.